The Question

Here is the specific thing we are predicting: will a drug that genuinely halts Alzheimer's disease — stops it in its tracks — receive regulatory approval by 2035? Our model says 44% probability. That is nearly a coin flip, and deliberately so. The question matters because two drugs, lecanemab and donanemab, were approved by the FDA in 2023 and 2024. For the first time in history, after more than 200 failed trials, we have medicines that demonstrably change the course of Alzheimer's. That is a real milestone. But "27% slower decline over 18 months" is not the same as stopping the disease. The next decade will tell us whether these approvals were the first step toward a cure or the ceiling we were always heading for.

Neuroscience laboratory with brain scan imagery

Alzheimer's has beaten medicine for decades. The reason is brutally simple: the disease starts damaging the brain 15 to 20 years before any symptoms appear, and by the time you forget your keys regularly, enormous damage has already been done. Earlier drugs failed because they couldn't clear the sticky protein clusters — called amyloid plaques — that build up in the brain. Lecanemab and donanemab can clear them. That is why they work, at least partially. The question is what comes next.

What the Evidence Shows

"Blood-based biomarkers are reshaping how we identify and understand Alzheimer's disease."

— Maria C. Carrillo, Chief Science Officer, Alzheimer's Association, May 2025

The current drugs work by targeting amyloid — a protein that clumps into plaques between brain cells. Clear the plaques and you slow the disease. It sounds straightforward, but it took 30 years and hundreds of failed attempts to get here. The new drugs work. They just don't work enough. A 27% slowing of decline is real, but it still means decline. Researchers are now turning to the next target: tau protein, which forms tangled knots inside brain cells (called neurofibrillary tangles) and correlates even more closely with how much memory and thinking ability a patient loses. Anti-tau drugs are now in clinical trials. The hypothesis is that combining amyloid-clearing drugs with tau-targeting drugs could stop the disease rather than slow it. Not every promising idea survives: in November 2025, two large trials of semaglutide — the drug behind Ozempic — in early Alzheimer's failed to slow the disease, despite improving some biomarkers.

27% slower decline is not nothing — but it is not the cure that 57 million patients and their families are waiting for.

The single most exciting development right now isn't a drug at all. It is a blood test. Blood tests that measure a protein called p-tau217 can now detect Alzheimer's pathology with around 90% accuracy, and in May 2025 the FDA cleared the first blood test to help diagnose Alzheimer's, for adults 55 and older with symptoms. Think about what that means. The drugs we have work best in early disease. If you can identify people who are heading toward Alzheimer's a decade before they notice anything, you can treat them early enough to actually prevent the worst. The problem is that most health systems aren't yet set up to act on the result.

Why This Is Happening

The numbers are staggering. About 57 million people worldwide were living with dementia in 2021, according to the World Health Organization, and the Global Burden of Disease study projects around 153 million by 2050. Most of the cost — financial and human — falls on family caregivers, predominantly women, who provide unpaid care for years. No health system in the world is currently equipped to manage this at scale. That pressure is a large part of why research funding has accelerated so dramatically.

Lifestyle matters more than most people think. The 2024 Lancet Commission on dementia identified fourteen modifiable risk factors — including high blood pressure, high LDL cholesterol, obesity, smoking, physical inactivity, depression, social isolation, hearing loss and untreated vision loss — and estimated that nearly half of dementia cases could, in theory, be prevented or delayed by addressing them. Exercise has the strongest prevention evidence of anything currently known, improving blood flow to the brain and stimulating chemicals that help brain cells survive. Sleep matters too: the brain's waste-clearance system flushes out amyloid and tau during sleep, and chronic poor sleep may be quietly accelerating Alzheimer's pathology in millions of people.

Cost is already a crisis. Lecanemab costs $26,500 a year. Medicare in the US covers it, but with significant administrative barriers that make access difficult in practice. Europe's drug regulator initially recommended against it, arguing the modest benefit didn't outweigh the risks — which include brain swelling and small bleeds in some patients — before both lecanemab and donanemab were authorised in the EU in 2025 for a restricted group of patients. In England, NICE recommended against routine NHS use on cost-effectiveness grounds, though it agreed to look again after appeals. The result is a drug that exists, works partially, and remains out of reach for most people who could benefit from it.


What Could Happen

By 2035: Combination Therapy Halts Progression in Early Patients Possible

Amyloid-clearing drugs are combined with tau-targeting drugs in major trials by 2027–2028. The combination approaches disease-halting rather than mere slowing. Blood tests identify at-risk people years early, allowing treatment before symptoms start. The FDA approves a disease-halting regimen by 2034–2035. Alzheimer's begins the shift from a death sentence to a manageable condition.

By 2035: Better Management But No Halt — The Plateau Scenario Most likely

Existing drugs improve and become cheaper. Tau-targeting drugs add modest benefit on top. Alzheimer's becomes somewhat more treatable but a genuine halt remains out of reach by 2035. Prevention through lifestyle changes and early blood testing reduces new cases in wealthier countries more effectively than any drug. Progress — but not the breakthrough.

By 2030: Blood Tests Enable Prevention Before Symptoms Appear Possible

The p-tau217 blood test becomes routine screening by 2028. A major prevention trial shows that treating people before any symptoms appear dramatically reduces disease onset. This doesn't help existing patients immediately, but it changes the trajectory — Alzheimer's shifts from a treatment problem to a prevention problem, and the future burden curve bends downward.

The Forecast The World Verdict
We assign 44% probability that a treatment demonstrably halting Alzheimer's progression in early-stage patients receives regulatory approval by 2035. Lecanemab and donanemab proved the concept works — amyloid clearance does slow the disease. That is genuinely new, after two decades of failure. Tau-targeting drugs entering trials now represent the next frontier; the bet is that combining both approaches produces something closer to a halt than a slowdown. The p-tau217 blood test creates the diagnostic window to catch people early enough for prevention to work. The 56% probability of missing the 2035 threshold reflects hard biological realities: Alzheimer's involves multiple interacting systems, combination therapies need years of trial work to prove safe and effective, and regulatory timelines are tight even if the science delivers. The prevention story — exercise, sleep, blood pressure control, early testing — may ultimately move the needle more than any drug approved before 2035. It just doesn't make headlines the same way.

What Can We Do

Senior person exercising with caregiver support

You don't need to wait for a drug approval to reduce your risk. Regular physical activity is consistently associated with a lower risk of dementia in large studies, and physical inactivity is one of the Lancet Commission's fourteen risk factors. Controlling blood pressure, keeping a healthy weight, not smoking, and staying socially connected all chip away at the same risk. None of these are guarantees. But they are real, free, and available right now.

Health systems have a different job: build the infrastructure that the new testing era demands. Blood tests can now help identify Alzheimer's pathology far more cheaply and easily than brain scans or spinal taps. But a positive test result is only useful if there are memory clinics, trained specialists, and reimbursed treatments waiting at the end of the referral pathway. Most health systems don't have that yet. Building it now — before the next wave of drugs arrives — is the smartest move policymakers could make.

For researchers and funders, the case for sustained investment has never been stronger. US federal funding for Alzheimer's and dementia research at the NIH has risen roughly sevenfold since 2011, to more than $3.5 billion a year, according to the Alzheimer's Association — and the first disease-modifying drugs vindicate that spending. The next phase — combination therapies, prevention trials, gene-based approaches targeting the APOE4 risk gene — needs that funding to continue. This is not the moment to slow down.